Treatment-induced NE prostate cancer (NEPC) and lung cancer, which display small cell–like carcinoma features and increased expression of neuronal markers, such as synaptophysin (SYP), chromogranin A (CHGA), and neuron-specific enolase (NSE), are highly aggressive and lack effective clinical interventions (3, 4). The gene discussed is ENO2; the disease is carcinoma.